BYSI BeyondSpring Price Target

BYSI BeyondSpring drug, plinabulin, increased overall survival and improved other measures of disease while staving off a dangerous side effect associated with Chemotherapy.

BeyondSpring is preparing to ask for plinabulin approval in the U.S. and China.

On 8/4/2021 J. Pantginis from HC Wainwright brokerage Upgraded BYSI BeyondSpring from Neutral to Buy giving a Price Target of $100.00

My price target is the all time high resistance of 48usd until we hear some news from the FDA.